The therapeutic landscape for complement-mediated diseases (e.g., PNH) has expanded significantly with the development of inhibitors targeting various points in the cascade, including C5, C3, and Factor B (Ricklin et al., 2019; Morgan and Harris, 2015). This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.